2024
Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer
Koehne E, Bakaloudi D, Ghali F, Nyame Y, Schade G, Grivas P, Yezefski T, Hawley J, Yu E, Hsieh A, Montgomery R, Psutka S, Gore J, Wright J. Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer. Clinical Genitourinary Cancer 2024, 22: 102100. PMID: 38763862, DOI: 10.1016/j.clgc.2024.102100.Peer-Reviewed Original ResearchNational Cancer DatabaseAdjuvant chemotherapyReceipt of ACRadical cystectomyBladder cancerOverall survivalAssociated with significantly longer OSAssociated with OS benefitNon-metastatic bladder cancerMultivariate Cox regression analysisPrevalence of adenocarcinomaSquamous cell histologyMultivariate Cox regressionCox regression analysisMultivariate logistic regressionAssociated with lower oddsAssociated with greater oddsNeuroendocrine histologyLonger OSOS benefitCell histologyHistological subtypesCancer DatabaseClinicopathological featuresCox regression
2021
A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group)
Wu Z, Chen Q, Djaladat H, Minervini A, Uzzo R, Sundaram C, Rha K, Gonzalgo M, Mehrazin R, Mazzone E, Marcus J, Danno A, Porter J, Asghar A, Ghali F, Guruli G, Douglawi A, Cacciamani G, Ghoreifi A, Simone G, Margulis V, Ferro M, Tellini R, Mari A, Srivastava A, Steward J, Al-Qathani A, Al-Mujalhem A, Bhattu A, Mottrie A, Abdollah F, Eun D, Derweesh I, Veccia A, Autorino R, Wang L. A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group). European Urology Focus 2021, 8: 173-181. PMID: 33549537, DOI: 10.1016/j.euf.2021.01.014.Peer-Reviewed Original Research